TRxADE HEALTH (NASDAQ:MEDS) is set to unveil its quarterly earnings results on Wednesday, December 13th. As investors eagerly await the financial update, let’s take a closer look at how the stock has been performing and what experts are saying about its future prospects.
Shares of NASDAQ MEDS experienced a slight dip of $0.01 during midday trading on Tuesday, reaching $6.15. Although this may seem like a small fluctuation, it’s important to note that 519 shares of the stock were exchanged, compared to its average volume of 251,709. TRxADE HEALTH currently has a 50-day simple moving average of $6.12 and a 200-day simple moving average of $7.51.
With a market capitalization of $4.18 million, TRxADE HEALTH has faced its fair share of challenges. The stock has a P/E ratio of -0.97 and a beta of 1.83, which indicates a higher level of volatility compared to the overall market. Over the past year, TRxADE HEALTH has seen a low of $3.76 and a high of $19.70.
Institutional investors have also shown interest in TRxADE HEALTH. Barclays PLC recently purchased 4,801 shares of the company’s stock, valued at approximately $63,000. This represents about 0.71% ownership of TRxADE HEALTH. Overall, institutional investors and hedge funds own 4.12% of the company’s stock, highlighting their confidence in its potential.
TRxADE HEALTH, Inc operates as a health services IT company in the United States. The company focuses on digitalizing the retail pharmacy experience by optimizing drug procurement, prescription journey, and patient engagement. Through its TRxADE drug procurement marketplace, TRxADE HEALTH offers price transparency, purchasing capabilities, and other value-added services. Additionally, the company provides patient-centric telehealth services under the Bonum Health brand name.
As the anticipation builds for TRxADE HEALTH’s quarterly earnings release, investors and analysts will closely analyze the financial results and outlook. Stay tuned for the latest news and updates on TRxADE HEALTH’s performance in the stock market.
